Summary:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center
Study with an Open-Label Extension to Assess the Efficacy and Safety of
ITI-007 Monotherapy in the Treatment of Patients with Major Depressive
Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar
Depression)
Qualified Participants Must:
• Between 18-75
•
Be either male or female
Qualified Participants May Receive:
Compensation for time and travel